Managing elevated blood lipid concentrations. Who, when and how?
- PMID: 2184006
- DOI: 10.2165/00003495-199039030-00004
Managing elevated blood lipid concentrations. Who, when and how?
Abstract
Patients with elevated serum cholesterol concentrations, particularly men, should be treated to lessen their chance of subsequent morbidity from coronary heart disease. Reduction of elevated triglyceride levels is more contentious, but is justified in severely affected individuals. The levels requiring treatment can only be judged by consideration of the overall clinical setting, including patient age and sex, the presence of other risk factors and the particular lipoprotein abnormality. In general, relative youth, male sex, a low level of high density lipoprotein (HDL) cholesterol and a strong family history of coronary heart disease will favour vigorous therapy. The possibility that hyperlipoproteinaemia is secondary to some other metabolic disorder should be considered, particularly in regard to elevated triglyceride levels.
Similar articles
-
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.Drugs. 1996 Nov;52(5):725-53. doi: 10.2165/00003495-199652050-00008. Drugs. 1996. PMID: 9118820 Review.
-
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.Drugs. 2004;64(11):1181-96. doi: 10.2165/00003495-200464110-00003. Drugs. 2004. PMID: 15161326 Review.
-
The triglyceride-high-density lipoprotein axis: an important target of therapy?Am Heart J. 2004 Aug;148(2):211-21. doi: 10.1016/j.ahj.2004.03.037. Am Heart J. 2004. PMID: 15308990 Review.
-
Overview of current issues in management of dyslipidemia.Am J Cardiol. 1993 Feb 25;71(6):3B-8B. doi: 10.1016/0002-9149(93)90138-3. Am J Cardiol. 1993. PMID: 8434559 Review.
-
Management of protease inhibitor-associated hyperlipidemia.Am J Cardiovasc Drugs. 2002;2(2):91-106. doi: 10.2165/00129784-200202020-00003. Am J Cardiovasc Drugs. 2002. PMID: 14727985 Review.
Cited by
-
Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.Pharmacoeconomics. 1992 Feb;1(2):124-45. doi: 10.2165/00019053-199201020-00009. Pharmacoeconomics. 1992. PMID: 10146941 Review.
-
Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols.Pharmacoeconomics. 1998;14 Suppl 3:29-38. doi: 10.2165/00019053-199814003-00004. Pharmacoeconomics. 1998. PMID: 10346426 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources